Arrowhead Pharmaceuticals to Present at Upcoming May Conferences
April 29 2016 - 7:30AM
Business Wire
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced
that the company will make presentations at the following upcoming
events.
Arteriosclerosis, Thrombosis and Vascular Biology |
Peripheral Vascular Disease (ATVB|PVD) 2016 Scientific Sessions
– Nashville, May 5-7, 2016
May 6, 11:00 a.m. CDT – Stacey Melquist,
Ph.D., Arrowhead senior scientist, and coauthors, will deliver a
poster presentation titled, “Lipoprotein(a) targeting with RNAi
delivery platforms in transgenic mice and cynomolgus monkeys”
(Presentation Number 428)
IBC’s 18th Annual TIDES: Oligonucleotide and
Peptide Therapeutics – Long Beach, California, May 9-12,
2016
May 9, 1:30 p.m. PDT – David Rozema, Ph.D.,
Arrowhead vice president of chemistry will deliver an oral
presentation titled, “Protease-sensitive endosomal escape for
delivery of siRNA in vivo”
May 9, 1:30 p.m. PDT – Qingguo Tian, Ph.D.,
Arrowhead bioanalytical project manager will deliver an oral
presentation titled, “Sensitive and specific quantification of
oligonucleotides in biological matrices using hybridization based
LC-fluorescence assays”
5th Asian Conference on Hepatitis and AIDS (ACHA) –
Nanjing, China, May 28-29, 2016
May 29, 4:50 p.m. CST (China Standard Tim) –
Bruce Given, M.D., Arrowhead chief operating officer will deliver
an oral presentation titled, “RNAi therapeutics for chronic HBV
- Animal models”
Copies of presentation materials can be accessed on the Events
and Presentations page under the Investors section of the Arrowhead
website after each presentation is delivered.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat
intractable diseases by silencing the genes that cause them. Using
a broad portfolio of RNA chemistries and efficient modes of
delivery, Arrowhead therapies trigger the RNA interference
mechanism to induce rapid, deep, and durable knockdown of target
genes. RNA interference, or RNAi, is a mechanism present in living
cells that inhibits the expression of a specific gene, thereby
affecting the production of a specific protein. Arrowhead’s
RNAi-based therapeutics leverage this natural pathway of gene
silencing. The company’s pipeline includes ARC-520 and ARC-521 for
chronic hepatitis B virus infection, ARC-AAT for liver disease
associated with alpha-1 antitrypsin deficiency, ARC-F12 for
hereditary angioedema and thromboembolic disorders, ARC-LPA for
cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.
For more information please visit www.arrowheadpharma.com, or
follow us on Twitter @ArrowheadPharma. To be added to the Company's
email list and receive news directly, please visit
http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:
This news release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our
actual results may differ materially and adversely from those
expressed in any forward-looking statements as a result of various
factors and uncertainties, including our ability to finance our
operations, the future success of our scientific studies, our
ability to successfully develop drug candidates, the timing for
starting and completing clinical trials, rapid technological change
in our markets, and the enforcement of our intellectual property
rights. Our most recent Annual Report on Form 10-K and subsequent
Quarterly Reports on Form 10-Q discuss some of the important risk
factors that may affect our business, results of operations and
financial condition. We assume no obligation to update or revise
forward-looking statements to reflect new events or
circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Pharmaceuticals, Inc.
Source: Arrowhead Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160429005194/en/
Arrowhead Pharmaceuticals, Inc.Vince Anzalone,
CFA626-304-3400ir@arrowheadpharma.comorInvestor
Relations:The Trout GroupChad Rubin,
646-378-2947ir@arrowheadpharma.comorMedia:Russo PartnersMatt
Middleman, M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024